Treatment of Peyronie's Disease
with Local lnterferon-a2b

Wegner, H; Andresen, Reimer; Knipsel, Helmut H.; Miller, Kurt

doi:10.1159/000475057

Cited by 64 publications

(37 citation statements)

References 17 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…43,44 Our in vitro studies using human cavernosal cell culture demonstrated stimulation of collagen production on exposure to oxygen-free radicals and diminished collagen production in the presence of interferon alpha. 45,46 Furthermore, interferon alpha 2b is recognized to effectively decrease keloid scars and scleroderma. 47 Based on the success of intralesional collagenase and verapamil and the recognized in vitro effects of interferon alpha, the first report with intralesional interferon alpha 2b demonstrated decreased penile pain, penile curvature, and plaque size.…”

Section: Role Of Antioxidants In Peyronie's Diseasementioning

confidence: 99%

Role of oxidative stress and antioxidants in Peyronie's disease

2002

View full text Add to dashboard Cite

Section: Role Of Antioxidants In Peyronie's Diseasementioning

confidence: 99%

Role of oxidative stress and antioxidants in Peyronie's disease

2002

View full text Add to dashboard Cite

“…Therapeutic strategies that have been employed include oral, intralesional and transdermal agents. [13][14][15][16] Unfortunately, large-scale, prospective, placebo-controlled studies of these treatments in humans are lacking and are complicated to design, making it difficult to compare the value of different treatments. The availability of an animal model would be invaluable to the study of the effect of different treatments on this disease process.…”

Section: Introductionmentioning

confidence: 99%

Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model

Martín

Lubrano

et al. 2004

Int J Impot Res

View full text Add to dashboard Cite

“…Wegner et al ®rst found an effect in early, non calci®ed lesions, but then later published an article stating that interferonalpha-2b is not effective. 34,35 Judge et al, found a minimal positive objective effect on patients with smaller plaques, while Lue argued against the effectiveness of local interferon in 1998. 36,37 Ahuja et al, reported a signi®cant improvement in pain and curvature in their 1999 article.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents

et al. 2000

View full text Add to dashboard Cite

Peyronie's disease is a ®bromatosis of the tunica albuginea which affects up to 2% of men. Plaque development is believed to result, at least in part, from ®broblast proliferation and excess collagen deposition. Numerous oral and intralesional therapies have been used, including verapamil, colchicine and steroids. The purpose of this study was to investigate the in vitro effects of prostaglandin-E1 (PGE1), verapamil and colchicine on the proliferation rates of ®broblasts derived from Peyronie's disease tissue.Using tissue culture, multiple cell lines comprising ®broblasts from Peyronie's plaque, normal tunica and foreskin were established. Cells of low passage were removed from the parent culture and incubated with varying concentrations of PGE1 (0.1 ± 10 mgaml), verapamil (10 ± 1000 mgaml), and colchine (2.5 mgaml). Proliferation was assessed at 48, 72 and 96 hours using the Vybrant TM MTT cell proliferation and then compared to control cells.Six plaque lines and 5 normal tunical cell lines were established. These cell lines exhibited excellent linear growth in culture media alone. Co-culture wih PGE1 resulted in no signi®cant inhibition at 0.1 and 1 mgaml, but a mean inhibition of 60.6 AE 11.5% at a concenrtation of 10 mgaml was noted. Similar inhibition was noted with verapamil at 100 and 1000 mgaml with a mean inhibition of 65.2 AE 10.6%. Colchicine resulted in a mean inhibition of 28% at a concentration of 2.5 mgaml. Maximum inhibition occurred at 96 hours in all cases. There was no statisitically signi®cant difference in proliferation rates between plaque and normal tunical cell lines.We have developed an in vitro model to assess the effects of biologically active agents on the growth of ®broblasts derived from Peyronie's disease tissue. Our data suggests that PGE1, verapamil, and colchicine inhibit in vitro proliferation of ®broblasts at speci®c concentrations. Re®nement and application of this knowledge may allow the development of useful pharmacologic strategies for men with PD.

show abstract

Treatment of Peyronie's Disease with Local lnterferon-a2b

Cited by 64 publications

References 17 publications

Role of oxidative stress and antioxidants in Peyronie's disease

Role of oxidative stress and antioxidants in Peyronie's disease

Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model

Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents

Contact Info

Product

Resources

About